局部应用盐酸布那唑嗪通过增加脉络膜血流灌注抑制近视进展
研究在3周龄C57BL/6J小鼠中使用-30屈光度镜片诱导近视三周,评估盐酸布那唑嗪(BH)滴眼液的效果。结果显示BH滴眼液抑制了屈光近视漂移、眼轴延长、脉络膜变薄和巩膜变薄,并增加了脉络膜血流灌注,效应呈剂量依赖性。作者认为BH滴眼液具有治疗近视的潜力,支持进一步在人体中研究其疗效。
要点
- BH滴眼液抑制了-30D镜片眼近视漂移(-13.65±5.69 D vs 2.55±4.30 D,P<0.001)。
- BH滴眼液抑制眼轴延长(0.226±0.013 mm vs 0.183±0.023 mm,P<0.05)。
- BH滴眼液抑制脉络膜变薄和巩膜变薄,并增加脉络膜血流灌注。
核心结论
- 结果表明BH滴眼液具有治疗近视的潜力,并支持进一步研究其在人体中的疗效。
- 需要进一步研究以确定该治疗的作用机制和长期安全性。
研究设计与样本
- 在3周龄C57BL/6J小鼠中使用-30屈光度(D)镜片诱导近视三周。
- 在3周龄和6周龄时使用红外光电验光仪和谱域光学相干断层扫描(OCT)系统评估屈光不正、眼轴长度和脉络膜厚度。
- 使用扫频源OCT和组织学分析评估脉络膜血流灌注(ChBP)和巩膜厚度。
主要发现
- 与对照组相比,BH滴眼液抑制了-30D镜片眼的屈光近视漂移(平均差±标准误:-13.65±5.69 D vs 2.55±4.30 D;P<0.001)。
- 与对照组相比,BH滴眼液抑制了眼轴延长(0.226±0.013 mm vs 0.183±0.023 mm;P<0.05)。
- 与对照组相比,BH滴眼液抑制了脉络膜变薄(-2.01±1.80 µm vs 1.88±1.27 µm;P<0.001)。
- 与对照组相比,BH滴眼液抑制了巩膜变薄(11.41±3.91 µm vs 19.72±4.01 µm;P<0.01)。
- 与对照组相比,BH滴眼液增加了脉络膜血流灌注(52.0%±4.1% vs 59.5%±6.3%;P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究以确定该治疗的作用机制和长期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The incidence of myopia has rapidly increased in recent decades, making it a growing public health concern worldwide. Interventions to suppress the progression of myopia are needed; one suggested strategy is the prevention of choroidal thinning, which can improve choroidal blood perfusion (ChBP). Bunazosin hydrochloride (BH) is an alpha1-adrenergic blocker and commercialized glaucoma eye drop that increases in blood circulation in the eye. In this study, we evaluated the efficacy of BH in suppressing the progression of myopia in a lens-induced murine model. METHODS: Lens-induced myopia was induced in 3-week-old C57BL/6 J mice with -30 diopter (D) lenses for three weeks. Refractive error, axial length, and choroidal thickness were evaluated at three and six weeks of age using an infrared photorefractor and a spectral domain optical coherence tomography (OCT) system. Moreover, ChBP and scleral thickness were evaluated using swept-source OCT and histological analysis. RESULTS: Compared with the controls, the administration of BH eye drops suppressed the myopic shift of refractive error (mean difference ± standard error in the eye with -30 D lens, -13.65 ± 5.69 D vs. 2.55 ± 4.30 D; P < 0.001), axial elongation (0.226 ± 0.013 mm vs. 0.183 ± 0.023 mm; P < 0.05), choroidal thinning (-2.01 ± 1.80 µm vs. 1.88 ± 1.27 µm; P < 0.001), and scleral thinning (11.41 ± 3.91 µm vs. 19.72 ± 4.01 µm; P < 0.01) with myopia progression and increased ChBP (52.0% ± 4.1% vs. 59.5% ± 6.3%; P < 0.05). The suppressive effect of BH eye drops was dose-dependent and higher than that of other glaucoma eye drops and alpha1 blockers. CONCLUSIONS: These results demonstrate the potential of BH eye drops in the treatment of myopia and support further investigation of their efficacy in humans. Further studies are needed to determine the mechanism of action and long-term safety of this treatment.
引用
- Jeong H, Lee D, Jiang X, et al. Topical Application of Bunazosin Hydrochloride Suppresses Myopia Progression With an Increase in Choroidal Blood Perfusion. Invest Ophthalmol Vis Sci. 2023. PMID: 37955611. doi:10.1167/iovs.64.14.15
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。